FDA urges USPTO to tackle rising drug costs
14-09-2021
Abbott gets restraining order against ex-VP in COVID-19 trade secrets dispute
05-11-2020
Jarretera / Shutterstock.com
The US Food and Drug Administration (FDA) will today announce that it plans to grant a Chinese-owned testing company an exclusive worldwide licence for a US government-owned patent covering a diagnostic test for the rapid detection of COVID-19.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
FDA, COVID-19, patent license, innovation, Advion, by Beijing Bohui Innovation Biotechnology Company, diagnostics, spectrometers, royalties
